- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 239/06 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
Patent holdings for IPC class C07D 239/06
Total number of patents in this class: 53
10-year publication summary
|
7
|
5
|
5
|
6
|
6
|
2
|
3
|
2
|
3
|
2
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Sika Technology AG | 2855 |
5 |
| Arbutus Biopharma Corporation | 177 |
3 |
| Bitop AG | 49 |
3 |
| Bristol-myers Squibb Company | 4872 |
2 |
| BASF SE | 20874 |
2 |
| Merck Patent GmbH | 5861 |
2 |
| The Board of Trustees of the University of Illinois | 2685 |
2 |
| Adeka Corporation | 1362 |
2 |
| Mitsubishi Gas Chemical Company, Inc. | 3452 |
2 |
| Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences | 170 |
2 |
| Southern Medical University | 45 |
2 |
| Inspirna, Inc. | 38 |
2 |
| Novartis AG | 10882 |
1 |
| The Regents of the University of California | 19859 |
1 |
| Merck Sharp & Dohme Corp. | 2200 |
1 |
| California Institute of Technology | 3973 |
1 |
| Astellas Pharma Inc. | 1088 |
1 |
| East China University of Science and Technology | 512 |
1 |
| Georgia State University Research Foundation, Inc. | 344 |
1 |
| Human Biomolecular Research Institute | 24 |
1 |
| Other owners | 16 |